Vitamin D and multiple sclerosis: evidence, limitations, and practical implications

Note: This article was previously published and has been updated according to scientific and informative criteria. It is for informational purposes only and does not replace the advice of your treating physician.

IN BRIEF

• There is strong epidemiological evidence that higher vitamin D levels are associated with a lower risk of developing multiple sclerosis (MS), but this does not equate to a proven "cure."
• Mendelian randomization genetic studies suggest that the relationship between 25-OH-vitamin D and MS risk is likely causal for disease onset.
• Randomized clinical trials in MS patients testing high-dose supplementation have yielded conflicting results: some show effects on radiological parameters, while others show no significant reduction in relapses or short-term progression.
• For those living with MS or at risk, the practical goal is to avoid vitamin D deficiency and discuss with their doctor the need to measure and correct levels; pharmacological doses should be evaluated on a case-by-case basis.

Abstract: what does science say?

Vitamin D is an environmental factor that has been studied for decades in relation to multiple sclerosis. Observational evidence indicates that populations with greater sun exposure and higher circulating 25-hydroxyvitamin D levels have a lower risk of developing MS; Mendelian randomization genetic research strengthens the hypothesis that this association is partly causal for the risk of onset. However, when vitamin D has been tested as an add-on therapy in patients with established MS, the results of randomized trials are heterogeneous: some show reductions in radiological parameters, while most do not demonstrate a clear reduction in relapses or disability in the available follow-up period. Differences depend on dose, duration, study population, and concomitant therapies. In conclusion, vitamin D is plausibly relevant for the risk of developing MS and for some biological measures of disease activity, but there is currently no solid evidence that vitamin D alone "cures" MS. Clinical management requires diagnostic measures, prudence in dosing, and integration into the overall therapeutic framework under medical supervision.

Why vitamin D is considered relevant in MS

The relationship between latitude, sun exposure, and MS prevalence has been observed since historical epidemiological studies: areas further from the equator tend to show higher rates of MS, suggesting that insolation and its effects on cutaneous vitamin D production may be important environmental factors. Studies on large cohorts and serum samples have documented that higher circulating 25-hydroxyvitamin D levels are associated with a reduced risk of developing the disease. This evidence supports the biological plausibility that vitamin D, through immunomodulatory effects, could reduce the likelihood of an autoimmune process being triggered against the central nervous system. It is important to emphasize that association is not automatically proof of therapeutic efficacy: the role of vitamin D in preventing onset and as a modulator of disease activity are two distinct issues that require different studies.

Observational and genetic evidence

Prospective studies and cohort analyses have shown that higher dietary intake or higher serum levels of 25-OH-vitamin D are associated with a lower incidence of MS in the general population. Furthermore, genetic analyses using variants associated with vitamin D levels (Mendelian randomization) provide support for a causal effect: individuals with genetic profiles that predict lower 25-OH-vitamin D levels show a higher risk of developing MS. These techniques reduce the confounding bias typical of observational studies and increase confidence in the etiological role of vitamin D in determining susceptibility to the disease. However, these results concern the onset of MS and do not necessarily imply that high supplementation, initiated after diagnosis, produces the same risk reduction or improves short-term clinical outcomes.

Experimental and clinical evidence

To evaluate vitamin D as an add-on therapy in MS patients, randomized trials of different sizes and dosages have been conducted. Some phase II and III studies have used high doses to achieve marked increases in serum levels; exploratory results have in some cases shown a reduction in active lesions on magnetic resonance imaging, while the primary endpoint of reducing relapses or worsening disability has not been reached in multiple trials. Recent meta-analyses and systematic reviews, combining available trials, note methodological heterogeneity and the absence of a robust and consistent clinical effect on relapses and EDSS in most studies. Overall, experimental evidence suggests that vitamin D can modulate some biological and radiological parameters, but currently does not support the use of vitamin D alone as an established disease-modifying treatment for MS.

What this means in practice

For patients and professionals: measuring vitamin status (25-OH-vitamin D) in people at risk or with MS can be useful to identify and correct deficiency, which is known to have negative effects on bone health and probably on the immune system. Clinical trials do not justify the generalized use of very high doses of vitamin D as a sole therapy for MS in daily practice. Correcting deficiency to levels considered appropriate by guidelines for bone and metabolic health is reasonable, and when considering the use of pharmacological doses, the decision should be made with the neurologist or treating physician, evaluating concomitant medications, kidney function, and the risk of hypercalcemia. In summary: avoiding deficiency is recommendable; using high-dose supplements as a "cure" is not supported by the totality of the evidence.

Dose, form, and duration: what we know

Clinical trials have experimented with highly variable doses: from modest daily supplementation to regimens that lead to very high serum levels. Some studies have used cholecalciferol (vitamin D3) in high doses for 6–24 months; others have preferred intermittent or lower doses. In the most recent large trials, no consistent reduction in relapses emerged with doses of 5,000 IU/day or even higher regimens when used as an add-on to disease-modifying therapies. Medium-term safety appears acceptable in the studied contexts, but attention is needed for possible metabolic effects and hypercalcemia in the presence of very high doses or predisposing conditions.

Who can benefit from monitoring and supplementation

People with limited sun exposure, dark skin type, malabsorption, therapies that affect vitamin metabolism, or signs of bone fragility represent groups in whom the measurement and correction of 25-OH-vitamin D levels are particularly relevant. The decision to start supplementation and the dosage depend on the baseline value, age, comorbidities, and use of medications. It is advisable not to prescribe pharmacological doses without biological and medical monitoring.

KEY POINTS TO REMEMBER

• Vitamin D is associated with a lower risk of MS onset in observational and genetic analyses, but it has not been proven as a curative therapy for established disease.
• Randomized studies in MS patients have yielded heterogeneous results: some radiological improvements have been reported, but the effect on relapses and disability is not consistent.
• Correcting vitamin deficiency is a prudent measure for general and bone health; high-dose supplementation must be evaluated and monitored by a doctor.
• Research continues: new trials, combined analyses, and long-term studies are needed to clarify the dose, duration, and populations that could benefit.

Limitations of the evidence

The main limitations must be kept in mind when reading the data. Observational studies (cohorts, case-control) show associations but are susceptible to confounding and measurement bias; therefore, they do not prove causality alone. Mendelian randomization genetic analyses offer causal support for the role of vitamin D in the risk of MS onset, but these analyses do not say whether supplementation after diagnosis modifies the disease. Clinical trials show heterogeneity in dose, duration, primary endpoints, and concomitant therapies; many are of limited size and with relatively short follow-up for the chronic nature of MS. Furthermore, most clinical endpoints (relapses, disability progression) require large samples and long follow-ups to be evaluated with statistical power. Finally, the impact of variables such as ethnicity, metabolic status, sun exposure, and concomitant pharmacology complicates the interpretation and generalization of results.

Editorial conclusion

In light of current evidence, vitamin D is a relevant biological factor in the study of the origin and modulation of multiple sclerosis. There are consistent signals that higher 25-OH-vitamin D levels are associated with a lower risk of developing MS; genetic analyses strengthen the hypothesis of a causal role in the onset phase. However, the results of clinical studies in patients with established MS are not sufficient to consider vitamin D a reliably proven "disease-modifying" therapy. In clinical practice, the most reasonable measure is to prevent and correct deficiency, pursuing a balance between efficacy, safety, and medical monitoring. Future research will need to clarify dosages, timing, and patient subgroups that could obtain concrete benefits from targeted supplementation strategies.

EDITORIAL NOTE

This article has been updated according to scientific verification and communication clarity criteria. The information provided is for informational purposes and does not replace medical consultation. For therapeutic decisions or interpretation of test results, it is recommended to consult your specialist.

SCIENTIFIC RESEARCH

1. Ascherio A, Munger KL, Levin LI, Hollis BW, Howard NS. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296(23):2832–2838. https://doi.org/10.1001/jama.296.23.2832
2. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62(1):60–65. https://doi.org/10.1212/01.WNL.0000101723.79681.38
3. Mokry LE, Ross S, Ahmad OS, et al. Vitamin D and risk of multiple sclerosis: a Mendelian randomization study. PLoS Med. 2015;12(8):e1001866. https://doi.org/10.1371/journal.pmed.1001866
4. Simon KC, Munger KL, Kraft P, et al. Genetic predictors of 25-hydroxyvitamin D levels and risk of multiple sclerosis. J Neurol. 2011;258(3): (see original). https://doi.org/10.1007/s00415-011-6001-5
5. Hupperts R, Smolders J, Vieth R, et al. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a (SOLAR). Neurology. 2019;93(20):e1906–e1916. https://doi.org/10.1212/WNL.0000000000008445
6. Dörr J, Bäcker-Koduah P, Wernecke KD, et al. High-dose vitamin D supplementation in multiple sclerosis – results from the randomized EVIDIMS trial. Mult Scler Relat Disord. 2020. https://doi.org/10.1177/2055217320903474
7. Cassard SD, Fitzgerald KC, Qian P, et al. High-dose vitamin D3 supplementation in relapsing-remitting multiple sclerosis: a randomised clinical trial (VIDAMS). EClinicalMedicine. 2023;59:101957. https://doi.org/10.1016/j.eclinm.2023.101957
8. The efficacy of vitamin D in multiple sclerosis: a meta-analysis. Mult Scler Relat Disord. 2018;23:56–61. https://doi.org/10.1016/j.msard.2018.05.008
9. Associations of serum 25(OH) vitamin D levels with clinical and radiological outcomes in multiple sclerosis: systematic review and meta-analysis. J Neurol Sci. 2020; (see original). https://doi.org/10.1016/j.jns.2020.116668